

# pUNO1-hSTING-β

Expression vector containing an isoform of human STING lacking exons 1-5

Catalog code: puno1-hsting-beta

<https://www.invivogen.com/hsting-beta>

For research use only

Version 19K10-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of lyophilized plasmid DNA
- 2 x 1 ml blasticidin at 10 mg/ml

### Storage and Stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable at least for 1 year.
- Store blasticidin at 4°C or -20°C.\*

\*The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and full-length open reading frame (ORF) sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

## GENERAL PRODUCT USE

- **Subclone gene into another vector.** Two unique restriction sites flank the gene, allowing convenient excision. The 5' site is BspEI which is compatible with AgeI, XmaI, NgoMIV and SgrAI. The 3' site is NheI which is compatible with XbaI, SpeI, and AvrII.
- **Stable gene expression in mammalian cells.** pUNO1 plasmids can be used directly in transfection experiments both *in vitro* and *in vivo*. pUNO1 plasmids contain the blasticidin-resistance gene (*bsr*) driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. This allows the amplification of the plasmid in *E. coli*, as well as the selection of stable clones in mammalian cells using the same selective antibiotic. pUNO1 allows high levels of expression and secretion of the gene product.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

## PLASMID FEATURES

- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic blasticidin. The *bsr* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, blasticidin can be used to select stable mammalian cells transfectants and *E. coli* transformants.
- **CMV promoter & enhancer** drives the expression of the blasticidin resistance in mammalian cells.

### • Human STING-β

**ORF size:** 696 bp

**Cloning fragment size:** 737 bp

STING (stimulator of interferon genes; also known as TMEM173, MITA, MPYS, and ERIS) is essential for the interferon (IFN) response to microbial or self-DNA, and acts as a direct sensor of cyclic dinucleotides (CDNs). CDNs are important messengers in bacteria, affecting numerous responses of the prokaryotic cell, but also in mammalian cells, acting as agonists of the innate immune response. hSTING-β, discovered in THP-1 cells, is an alternatively spliced isoform of hSTING lacking exons 1-5. It has been reported that hSTING-β acts as a dominant negative mutant of STING by suppressing IFN-regulatory factor and NF-κB activation by CDNs<sup>1</sup>. It has been proposed that hSTING-β inhibits IFN production by interacting with and sequestering STING, TBK1 and CDNs.

- **EF-1α/HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1α (EF-1α) core promoter<sup>2</sup> and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1α utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat<sup>3</sup> has been coupled to the EF-1α promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

- **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNA<sup>4</sup>.

- **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

- **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *bsr*. The use of beta-globin pAn minimizes interference<sup>5</sup> and possible recombination events with the SV40 polyadenylation signal.

1. Wang PH. et al., 2018. A novel transcript isoform of STING that sequesters cGAMP and dominantly inhibits innate nucleic acid sensing. *Nucleic Acids Res.* 46(8):4054-4071. 2. Kim D. et al., 1990. Use of the human elongation factor 1α promoter as a versatile and efficient expression system. *Gene* 91(2):217-23. 3. Takebe Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol.* 8(1):466-72. 4. Carswell S. & Alwine J., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol.* 9(10):4248-58. 5. Yu J. & Russell J., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

## RELATED PRODUCTS

Product	Description	Cat. Code
Blasticidin ChemComp GT116	Selection antibiotic Competent <i>E. coli</i>	ant-bl-1 gt116-11

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

 **InvivoGen**  
www.invivogen.com



**PvuI (7)**  
**SgfI (6)** **MfeI (82)**  
1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGAGAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTGGCAATTGAACGGGTGCCTA

101 GAGAAAGTGGCGCGGGTAAACTGGAAAGTGTCTGTACTGGCTCCGCCTTTTCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC

**HindIII (245)**  
**Psp1406I (203)** **PvuII (239)** **Bsu36I (291)**  
201 GTGAACGTTCTTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGCTCGCATCTCTCTTACCGCGCCGCCCTACCTGAGGGC

301 GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCTCCCGCCTGTGGTGCTCCTGAAGTGCCTCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC

**NgoMIV (441)**  
401 GGGCCTTTGTCCGGCGCTCCCTTGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTCCTGACCCTGCTTCTCAACTCTACGCTTTTGTTCGTTT

**BspEI (558)** **PshAI (570)**  
501 TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGGCGCTACCTGAGATCACCGGCTCCGGACAGCATGACCTGGTCTCACTCCTGAATCAGGTGGG  
1▶ M T W V S L L N Q V G

**XmnI (615)** **BstBI (659)**  
601 AGATAGGGTTAGCAGGAATAACTTCTGGGCTTCCTCGCTCAGAGCTCCAGGCCGGATTGAACTTACAATCAGCATTACAACAACCTGCTACGGGGT  
11▶ D R V S R N N F L G F P A S E L Q A R I R T Y N Q H Y N N L L R G

701 GCAGTGAGCCAGCGGCTGTATATTCTCCTCCATTGGACTGTGGGTGCTGATAACCTGAGTATGGCTGACCCCAACATTGCTTCTGGATAAACTGC  
45▶ A V S Q R L Y I L L P L D C G V P D N L S M A D P N I R F L D K L

**BstEII (811)** **AgeI (808)**  
801 CCCAGCAGACCGGTGACCGTGCTGGCATCAAGGATCGGGTTTACAGCAACAGCATCTATGAGCTTCTGGAGAACGGGCAGCGGGCGGGCACCTGTGCCT  
78▶ P Q Q T G D R A G I K D R V Y S N S I Y E L L E N G Q R A G T C V L

901 GGAGTACGCCACCCCTTGACACTTTGTTTGCATGTCAATAACAGTCAAGCTGGCTTTAGCCGGGAGGATAGGCTTGGACAGGCCAAACTCTTCTGC  
111▶ E Y A T P L Q T L F A M S Q Y S Q A G F S R E D R L E Q A K L F C

**PstI (1073)**  
1001 CGGACACTTGAGGACATCCTGGCAGATGCCCTGAGTCTCAGAACAACCTGCCCTCATTGCCTACCAGGAACCTGCAGATGACAGCAGCTTCTCGTGT  
145▶ R T L E D I L A D A P E S Q N N C R L I A Y Q E P A D D S S F S L

**BbsI (1161)**  
1101 CCCAGGAGTTTCCGGCACCTCGCGCAGGAGAAAAGGAAGAGGTTACTGTGGGCAGCTTGAAGACCTCAGCGGTGCCAGTACCTCCACGATGTCCCA  
178▶ S Q E V L R H L R Q E E K E E V T V G S L K T S A V P S T S T M S Q

**BstEII (1271)** **NheI (1295)**  
1201 AGAGCCTGAGCTCCTCATCAGTGAATGAAAAAGCCCTCCCTCTCCGACGGATTTCTTTGAGACCCAGGGTCACCAGGCCAGAGCCTCCAGTGTAG  
211▶ E P E L L I S G M E K P L P L R T D F S •

**MscI (1301)**  
1301 CTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCT

**HpaI (1433)** **MfeI (1444)**  
1401 TTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAACAACAACATTGCATTATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGTTTTTTAA

**EcoRI (1529)**  
1501 GCAAGTAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAACTTTAACCTCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGG  
1601 ATGAATAAGGCATAGGCATCAGGGGCTGTGCCAATGTGATTAGCTGTTGCAGCCTCACCTTCTTTCATGGAGTTAAGATATAGTGTATTTCCCAA

**SapI (1711)** **SspI (1768)** **Swal (1782)**  
1701 GGTGTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCACATTCCTTTTATAGTAAATATTCAGAAATAATTTAAATACATCATTGC

**EcoO109I (1843)**  
1801 AATGAAAATAAATGTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTATAATATCCCCAGTTTAGTAGTTGGACTTAGGAAACAAAGGAACCTT  
1901 TAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTTAGTTCTGGTGTACTTGAGGGGGATGAGTTCCTCAATGGTGGTTTTGACCAGCTTGCCAT  
141▶ • N R T Y K L P I L E E I T T K V L K G N

**BstXI (2072)**  
2001 TCATCTCAATGAGCACAAAGCAGTCAGGAGCATAGTCAGAGATGAGCTCTCTGCACATGCCACAGGGGCTGACCACCTGATGGATCTGCCACCTCATC  
120▶ M E I L V F C D P A Y D S I L E R C M G C P S V R I S R D V E D  
2101 AGAGTAGGGGTGCTGACAGCCAAATGGTGTCAAAGTCTTCTGCCGTTGCTCACAGCAGACCCAATGGCAATGGCTTTCAGCAGACAGTGCACCTG  
87▶ S Y P H R V A V I T D F D K Q G N S V A S G I A I A E A C V T V R

**StuI (2207)**  
 2201 CCAATGTAGGCCTCAATGTGGACAGCAGAGATGATCTCCCCAGTCTTGGTCTCTGATGGCCGCCCGACATGGTGCTTGTTCCTCATAGAGCATGGTGA  
 53 G I Y A E I H V A S I I E G T K T R I A A G V H H K N D E Y L M T I

**BspHI (2357)**  
 BbsI (2353)  
 XmnI (2349)  
 2301 TCTTCTCAGTGGCGACCTCCACCAGCTCCAGATCCTGCTGAGAGATGTTGAAGGTCTTCATGATGGCCCTCTATAGTGAGTCGTATTATACTATGCCGA  
 20 K E T A V E V L E L D Q Q S I N F T K M

**AseI (2415)**  
 2401 TATACTATGCCGATGATTAATTGTCAAACACAGCGTGGATGGCGTCTCCAGCTTATCTGACGGTTCCTAAACGAGCTCTGCTTATATAGACCTCCCACCG

**SpeI (2570)**  
 2501 TACACGCCTACCGCCATTTCGCTCAATGGGGCGGAGTTGTTACGACATTTTGAAAGTCCCGTTGATTTACTAGTCAAAACAACTCCCATTGACGTCA

**SnaBI (2698)**  
 2601 ATGGGGTGGAGACTTGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATA  
 2701 CGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAAGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACT

**NdeI (2803)**  
 2801 TGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGA

**PacI (2989)**  
 PstI (2982)  
**SdaI (2981)**  
**BspLU11I**  
 2901 ACATACGTCATTATTGACGTCAATGGGCGGGGTCGTTGGGCGGTGAGCCAGGCGGGCCATTTACCGTAAAGTTATGTAACGCTGCAGGTTAATTAAGAA  
 3001 CATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTTTTCCATAGGCTCCGCCCTGACGAGCATCACAAAAAT  
 3101 CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCTTTCCCTGGAAGCTCCCTCGTGCCTCTCTGTTCCGACCCTGC  
 3201 CGTTACCGGATACCTGTCCGCTTTCTCCCTCGGGAAGCGTGGCGTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCCGCTC

**ApaI (3313)**  
 3301 CAAGCTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGTAGTCCAACCCGGTAAGACACGACTTATCG  
 3401 CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCCTGAAGTGGTGGCCTAACTACGGCTACACTAGAA  
 3501 GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGG  
 3601 TTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAAAC

**EagI (3749)**  
 PacI (3729) SwaI (3738) **NotI (3748)**  
 3701 TCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGAATAAAATATCTTTATTTTCTTACATCTGTGTGTTGGTTTTTT  
 3801 GTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAACTAGCAAATAGGCTGTCCCAGTGCAAGTGCAAGTGCCAGAACA  
 3901 TTTCTCTATCGAA